Kara N Maxwell, MD, PhD

Assistant Professor of Medicine (Hematology-Oncology)
Member, Abramson Cancer Center
Staff Physician, Corporal Michael J. Crescenz Veterans Association Medical Center, Paid Employee 5/8ths
Department: Medicine
Graduate Group Affiliations
Contact information
BRB Room 810
421 Curie Blvd
Philadelphia, PA 19104
421 Curie Blvd
Philadelphia, PA 19104
Publications
Education:
BS (Genetics, Biochemistry)
University of Wisconsin-Madison, 1998.
PhD (Molecular and Cellular Biology)
Rockefeller University, 2006.
MD (Medicine)
Weill Cornell Medical College, 2007.
Permanent linkBS (Genetics, Biochemistry)
University of Wisconsin-Madison, 1998.
PhD (Molecular and Cellular Biology)
Rockefeller University, 2006.
MD (Medicine)
Weill Cornell Medical College, 2007.
Description of Clinical Expertise
cancer risk evaluation, breast cancer risk, hereditary breast ovarian cancer, Li Fraumeni Syndrome, Fanconi AnemiaDescription of Research Expertise
I am a Medical Oncologist with postdoctoral training in Cancer Genetics and PhD training in molecular and cellular biology. My research interests are in the genetics of human disease, particularly familial breast and prostate cancers, and in determinants of disease penetrance.Maxwell Lab
https://www.med.upenn.edu/kmaxwelllab/
We are a translational human genetics and genomics research laboratory studying mechanisms of tumor formation in inherited cancer syndromes. We have a focus on breast and prostate cancer, but are interested in the broad range of tumor types affected by DNA repair deficiency. We are using multi-omics analyses of human samples coupled with in vitro and in vivo modelling systems to understand how tumors form in patients with inherited cancers.
For our work in prostate cancer genetics, we leverage the resources of the Basser Center for BRCA (https://www.basser.org/), the Penn Medicine Biobank (https://www.itmat.upenn.edu/biobank/), the Veterans' Affairs and Prostate Cancer Foundation Partnership (https://www.pcf.org/va-partnership/) and the VA Million Veterans' Program (https://www.mvp.va.gov/). Dr. Maxwell is the Director of the Basser Center’s Men and BRCA program (https://www.basser.org/brca/brca-men).
We are actively involved in many aspects of basic, translational and clinical research in Li Fraumeni Syndrome, caused by germline TP53 disease causing variants. We are one of the founding members of the EDISYN consortium (https://www.edisyn.org/) to study early cancer detection in patients with Li Fraumeni Syndrome, and we are active participants in the LIFTUp study (https://liftupstudy.org/).
We take a multi-disciplinary approach, collaborating with our colleagues across basic science labs and the clinical arena. Our research is funded by the National Cancer Institute, the Veterans’ Affairs Office of Research amd Development, the Prostate Cancer Foundation, the Burroughs Wellcome Foundation, the Li Fraumeni Syndrome Association and the Basser Center for BRCA.
Contact us for more details on rotation and post-doc projects in the fields of:
- Prostate cancer genetics
- BRCA1/2 cancers in men
- Li Fraumeni Syndrome and TP53-related disorders
- Mutational signatures in Veteran tumors
Lab Members 2024-25:
Greg Kelly MS, Lab Manager
Caitlin Orr PhD, Penn Project Manager
Leslie Grush AuD, VA Project Manager
KJ Johnson, Lab Administrative Assistant
Heena Desai MS, Bioinformatician
Ryan Hausler MS, Bioninformatician
Renyta Moses, CAMB Cancer Biology PhD Student
Taylor Crawford, CAMB Cancer Biology PhD Student
Nabamita Boruah PhD, Postdoctoral Fellow
Anh Le DO, Medicine Intern
Maliha Tayeb, Clinical Research Coordinator
Michael Wang, Clinical Research Coordinator
Rosella Delgado, Genetic Counseling Assistant
Sophia Spiegel, Penn Medical Student
Jillian O'Toole, Penn MS GC Student
Selected Publications
Achatz MI, Villani A, Bertuch AA, Bougeard G, Chang VY, Doria AS, Gallinger B, Godley LA, Greer MC, Kamihara J, Khincha PP, Kohlmann WK, Kratz CP, MacFarland SP, Maese LD, Maxwell KN, Mitchell SG, Nakano Y, Pfister SM, Wasserman JD, Woodward ER, Garber JE, Malkin D.: Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res 31(10): 1831-1840, May 2025.Valle LF, Li J, Desai H, Hausler R, Haroldsen C, Chatwal M, Ojo M, Kelley MJ, Rebbeck TR, Rose BS, Rettig MB, Nickols NG, Garraway IP, Yamoah K, Maxwell KN: Somatic Tumor Next-Generation Sequencing in US Veterans With Metastatic Prostate Cancer. JAMA Netw Open 8(5): e259119, May 2025.
Spiegel SR, Orr C, Croom MJ, Edgar NU, Cahill SR, Le AN, Good M, Anson J, Feola S, Mehrhoff C, Naumer A, Vagher J, Maese LD, Garber JE, Maoz A, Katona BW, MacFarland SP, Maxwell KN: Colorectal neoplasia rates in Li Fraumeni syndrome. Cancer Research Apr 2025.
Perrino MR, Jongmans MCJ, Tomlinson GE, Greer MC, Scollon SR, Mitchell SG, Hansford JR, Schultz KAP, Kohlmann WK, Kalish JM, MacFarland SP, Das A, Maxwell KN, Pfister SM, Weksberg R, Michaeli O, Tabori U, Ney GM, Lupo PJ, Brzezinski JJ, Stewart DR, Woodward ER, Kratz CP: Update on Cancer and Central Nervous System Tumor Surveillance in Pediatric NF2-, SMARCB1-, and LZTR1-Related Schwannomatosis. Clin Cancer Res 31(8): 1400-1406, Apr 2025.
Gitto SB, Pantel AR, Maxwell KN, Pryma DA, Farwell MD, Liu F, Cao Q, O'Brien SR, Clark AS, Shah PD, McDonald ES: [18F]FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer. Commun Med 5(1): 90, Mar 2025.
Narasimhamurthy M, Le A, Boruah N, Moses R, Kelly G, Bleiweiss I, Maxwell KN, Nayak A: Clinicopathologic Features of Breast Tumors in Germline TP53 Variant-Associated Li-Fraumeni Syndrome. Am J Surg Pathol 49(3): 195-205, Mar 2025.
Demarest K, Anantharajah A, Maxwell KN, Rohanizadegan M, Bradbury A, Nathanson KL, McCarthy AM, Domchek SM, Nayak A, Shah PD: Pathogenic Germline Variants in Patients With Metaplastic Breast Cancer. JAMA Netw Open 8(2): e2460312, Feb 2025.
Corbett RJ, Kaufman RS, McQuaid SW, Vaksman Z, Phul S, Brown MA, Mason JL, Waszak SM, Zhang B, Zhong C, Desai H, Hausler R, Naqvi AS, Chroni A, Geng Z, Gonzalez EM, Zhu Y, Heath AP, Li M; Penn Medicine BioBank; Regeneron Genetics Center; Storm PB, Resnick AC, Maxwell KN, Cole KA, Waanders AJ, Bornhorst M, MacFarland SP, Rokita JL, Diskin SJ: Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric CNS tumors. medrxiv Page: 2025.02.04.25321499, Feb 2025.
Fernandes CJ, Du YK, Naumer A, Kagami LA, Le A, Good M, Duvall M, Powers J, Zelley K, Maese L, MacFarland S, Kohlmann W, Maxwell KN, Katona BW: Pancreatic Cancer Risk and Screening Outcomes in Li-Fraumeni Syndrome. Pancreas epub, Feb 2025.
Schultz KAP, MacFarland SP, Perrino MR, Mitchell SG, Kamihara J, Nelson AT, Mallinger PHR, Brzezinski JJ, Maxwell KN, Woodward ER, Gallinger B, Kim SY, Greer MC, Schneider KW, Scollon SR, Das A, Wasserman JD, Eng C, Malkin D, Foulkes WD, Michaeli O, Bauer AJ, Stewart DR.: Update on Pediatric Surveillance Recommendations for PTEN Hamartoma Tumor Syndrome, DICER1-Related Tumor Predisposition, and Tuberous Sclerosis Complex. Clin Cancer Res 31(2): 234-244, Jan 2025.